Wearable sensors with wide-ranging strain sensitivity eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
(LOS ANGELES) - The National Institutes of Health has jointly awarded a $3.9 million grant to Ali Khademhosseini, Ph.D., director and CEO of the Terasaki Institute for Biomedical Innovation (TIBI), and Rami Oklu, Ph.D., M.D., of the Mayo Clinic. The grant will be used to develop innovative drug delivery methods to treat liver cancer. TIBI, a leader in the field of bioengineering and personalized healthcare solutions, will draw upon their extensive experience with biomaterials to create more effective ways to target and destroy tumor cells. The project will also rely on the collaboration and clinical expertise of Prof. Oklu, a specialist in the treatment of oncologic patients.
Multicellular liver-on-a-chip for modeling fatty liver disease eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Credit: Khademhosseini Lab
(LOS ANGELES) - Although one may think of psychedelic pharmaceuticals as being dangerous and detrimental, scientists have been conducting experiments and clinical trials on some of them and have obtained positive results when testing them for medical use. Research has shown that drugs such as MDMA (a type of methamphetamine), LSD and psilocybin ( magic mushrooms ) can be of benefit in treating severe pain, anxiety, depression and certain mental illnesses. Successful outcomes have been achieved when using psychedelics for treating conditions such as post-traumatic stress disorder and addictions to alcohol and smoking, for example. In many cases, these treatments have benefited individuals who had unsuccessfully tried to treat their conditions by other methods.